TesoRx Pharma LLC and ASKA Pharmaceutical Co., Ltd. announced that, based on the successful results of recently completed preclinical PK study, they will be proceeding together in the preparation and execution of the upcoming Phase 1/2a trial of TesoRx's novel oral testosterone product, TSX-011. The parties anticipate that this study will be conducted in the US, and will include Japanese patients to expedite development in both regions. Under the terms of the collaboration, ASKA made an undisclosed payment to TesoRx for achieving this milestone.